Replies to post #220265 on Biotech Values

[north40000]

https://www.nytimes.com/2018/07/27/health/rebates-high-drug-prices-trump.html

But for JNJ, PFE, LLY, SGEN, ARYC, there is a sea of red in pharm/biotech land today...at least in the ones we follow.

[jbog]

Vinmantoo

You can't be serious about the patient pool drying up.

I sure can. It shouldn't be a payer situation whereas I wouldn't think they wouldn't be cutting back.

It could be that many HCV infected patients who live an risky lifestyle aren't deemed to be in a hurry to receive treatment.

I haven't dug deeper to see if the number of patients treated were released.